Sensitization of Therapeutic-Resistant Pancreatic Cancer by Cancer Cell-Specific Drug Delivery

Abstract

In the first year of this three-year project, we have completed tasks following the timeline of our Statement of Work. We synthesize large amount of HMCD-SIM, enough for the entire project. We determined therapeutic efficacy of the HMCD-SIM on pancreatic cancer cell lines; and confirmed the sensitization function of the HMCD-SIM. We have established two new pancreatic cancer cell lines, and tested assay conditions for measuring GASP-1 in clinical serum samples. For mechanistic investigation, we have identified IC50 of the HMCD-SIM in combination with GEM and CDDP in BXPC-3 and MiaPaCa-2 cells. A series IHC analyses were conducted to determine the expression of OATPs on pancreatic cancer cell lines and tumor specimens. Throughout these analyses, OATP1B3 is determined to be a subject for further mutagenesis studies. These works laid a solid foundation for second year mechanistic investigation of the molecular mechanism of HMCD-SIM mediated cancer cell killing.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2019
Accession Number
AD1088183

Entities

People

  • Leland W. Chung

Organizations

  • Cedars-Sinai Medical Center

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Bladder Cancer
  • Cancer
  • Cell Line
  • Cell Membrane
  • Cells
  • Cellular Structures
  • Chemotherapeutic Agents
  • Culture Techniques
  • Department Of Defense
  • Electronic Mail
  • Intracellular Membranes
  • Medical Personnel
  • Membranes
  • Mitochondria
  • Neoplasms
  • Professional Development

Fields of Study

  • Biology

Readers

  • Computational Modeling and Simulation
  • Oncology (Cancer Research).